August 29, 2018
FDA proposes not including three bulk drug substances that outsourcing facilities may use in compounding
Editor's Note
The Food and Drug Administration (FDA) on August 28 issued a notice proposing not to include three bulk FDA-approved drug substancesābumetanide, nicardipine hydrochloride, and vasopressināon the list that outsourcing facilities may use in compounding drug products.
The FDA is seeking public comment before finalizing their decision. Comments must be received by October 29, 2018.
Free Daily News
- Survey assesses continued impact of Change Healthcare cyberattack
- WHO sounds alarm on potential spread of bird flu
- Allison Massari to deliver hopeful, empowering keynote address at OR Manager Conference 2024
- Neurosurgery trial: Early evacuation improves long-term hemorrhage outcomes
- Drug shortages higher than ever
- FDA announces class 1 recalls for premixed embolic, infusion pump software
- Academic medical centers identify performance-improvement priorities
- Propofol anesthesia for colonoscopy could help find polyps, prevent cancer
- FDA Class 1 recall renews concern about historically problematic heart pumps
- New physician compensation report reveals modest pay gains but growing discontent with the profession
© Access Intelligence, LLC. All rights reserved. | Privacy Policy | Diversity, Equity, Inclusion & Belonging